Zeprumetostat plus azacitidine and liposomal mitoxantrone for relapsed/refractory peripheral T‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II, single-center trial in Suzhou, China plans to enroll about 26 adults with relapsed or refractory peripheral T‑cell lymphoma to receive up to six cycles of induction therapy with zeprumetostat, azacitidine, and liposomal mitoxantrone followed by up to two years of zeprumetostat maintenance for responders. The primary goal is to measure overall response rate, with secondary endpoints including progression-free survival, overall survival, and safety. Patients must have measurable disease and adequate organ function and will be monitored for hematologic and non-hematologic toxicities during treatment. The protocol also includes exploratory biomarker and genetic analyses to look for signals associated with response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Relapsed or refractory peripheral T-cell lymphoma after first-line or higher treatment.
2. Age ≥ 18 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.
4. Presence of measurable target lesions \[Note: Target lesions are defined as lesions with at least one longest diameter (LD) measurement \> 1.5 cm and longest perpendicular diameter (LPD) measurement ≥ 1.0 cm, as assessed by computed tomography (CT) or magnetic resonance imaging (MRI). A maximum of six target lesions can be selected\].
5. Adequate function of major organs must meet the following criteria:

   * Hematological parameters: HB ≥ 70 g/L, PLT ≥ 50 × 10\^9/L, NE ≥ 1.0 × 10\^9/L (Note: Patients who have not received transfusions or drugs to support NE, PLT, or HB increase within 1 week before screening are eligible. Patients with bone marrow involvement by lymphoma resulting in cytopenia are not restricted by this criterion).
   * Echocardiographic left ventricular ejection fraction ≥ 50%.
   * Creatinine ≤ 132 umol/L or creatinine clearance ≥ 60 ml/min.
   * ALT and AST ≤ 3 times the upper limit of normal.
6. Women of childbearing potential must have a negative pregnancy test. Both male and female patients must agree to use effective contraception during treatment and for 1 year thereafter.
7. Life expectancy of more than 3 months.
8. Voluntary signed informed consent form.

Exclusion Criteria:

1. Underwent major surgery or severe trauma within 2 weeks before enrollment, or significant adverse effects have not yet recovered.
2. Currently suffering from or having had other malignancies within 3 years before enrollment, except for cured basal or squamous cell carcinoma of the skin, superficial bladder cancer, prostatic intraepithelial neoplasia, and cervical carcinoma in situ.
3. History of stroke or intracranial hemorrhage within the past 3 months.
4. Presence of complications or medical conditions that may interfere with the conduct of the study or pose a significant risk to the patient, including but not limited to severe cardiovascular diseases (e.g., cardiac disease classified as New York Heart Association class III or IV, myocardial infarction within the past 6 months, unstable arrhythmias, or unstable angina) and/or severe pulmonary diseases (e.g., severe obstructive pulmonary disease and history of symptomatic bronchospasm).
5. Human immunodeficiency virus infection, or presence of uncontrollable active hepatitis C virus or hepatitis B virus infection.
6. Uncontrollable active infection.
7. Pregnant or breastfeeding women.
8. Any life-threatening disease, medical condition, or organ system dysfunction that may endanger the safety of the patient, as determined by the investigator.
9. Any condition that may interfere with the absorption or metabolism of zemtovistat, azacitidine, or doneda, or place the study results at unnecessary risk.
10. Lymphoma involvement of the central nervous system.
11. Presence of conditions judged by the investigator to interfere with full participation in the study; conditions posing significant risk to the subject; or conditions that may interfere with the interpretation of study data.

Where it's running

• The First Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Ting Xu, Doctor
• Email: 21132075@qq.com
• Phone: +86-512-67781831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing new drugs and combinations for relapsed or refractory peripheral T‑cell lymphoma

  This project will try different new drugs and drug combinations to see if they help people with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting at 19 sites Phase 1/2 The Lymphoma Academic Research Organisation · Angers and 19 other locations · NCT07018752

• Treatment for relapsed or refractory Peripheral T-cell Lymphoma using LIS1

  This study tests a new drug called LIS1 to see if it helps people with relapsed or hard-to-treat Peripheral T-cell Lymphoma feel better and if it's safe for them to use.

  Recruiting at 8 sites Phase 1/2 Xenothera SAS · Caen and 7 other locations · NCT06495723

• CD20 antibody to prevent early EBV activation after a first allogeneic stem cell transplant

  Researchers are testing whether a CD20 monoclonal antibody can prevent EBV activation in people aged 14 to 70 after their first allogeneic stem cell transplant.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Hefei, Anhui and 9 other locations · NCT07929974

• BEBT-908 treatment for MEF2D-rearranged B-ALL that has come back or isn’t controlled

  This study tests BEBT-908 given IV to see if it can help people aged 14–75 with MEF2D-rearranged B-cell precursor ALL who have relapsed, are refractory, or still have measurable disease after treatment.

  Recruiting Phase 1 The First Affiliated Hospital of Soochow University · Suzhou · NCT07854652

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML

  We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07672262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.